Mepires

Clarithromycin, the active ingredient in Mepires, is a macrolide antibiotic presented as a strength/form for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute sinusitis, bronchitis exacerbations, skin infections and is part of Helicobacter pylori eradication regimens. GNH USA supplies Mepires as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections of the respiratory, skin and gastrointestinal systems.

- Community‑acquired pneumonia: effective eradication of the causative bacteria and improvement of clinical outcomes. - Acute bacterial sinusitis: reduces infection and relieves sinus inflammation. - Acute bacterial exacerbations of chronic bronchitis: controls bacterial overgrowth and improves breathing. - Skin and soft‑tissue infections: targets susceptible organisms to resolve infection. - Helicobacter pylori eradication regimens: used in combination therapy to eliminate H. pylori infection.

Common side effects are generally mild and transient.

Common Side Effects: - Nausea - Diarrhea - Abdominal discomfort - Altered taste

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Clostridioides difficile‑associated colitis - QT interval prolongation

Before prescribing clarithromycin, consider the following precautions. - Liver function: assess hepatic status, as the drug is metabolized hepatically. - Cardiac risk: monitor QT interval in patients with known cardiac disease or electrolyte disturbances. - Allergy: avoid in individuals with a known macrolide hypersensitivity. - Renal impairment: adjust therapy in severe renal dysfunction. - Drug interactions: review concomitant medications that affect CYP3A4 or QT interval. - Store below 25°C: keep in the original container, protect from moisture and light.

Clarithromycin can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Co‑administration with other QT‑prolonging agents (e.g., quinolones, antiarrhythmics) may increase arrhythmia risk. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) can raise clarithromycin plasma levels. - Ergot derivatives may cause ergot toxicity when combined.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR regularly. - CYP3A4‑metabolized statins (e.g., simvastatin): increased risk of myopathy; consider dose adjustment or alternative statin.